Skip to main content
CSTL logo

Castle Biosciences, Inc.

CSTLNASDAQHealthcareDiagnostics & Research

$33.80Today:- (-)1Y +50.02%

As of Oct 15, 2026 close

Market cap
$1.03B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$17.72$44.28
Volume (live)
-
Avg. volume (3M)
347.13K

Castle Biosciences (CSTL) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Castle Biosciences generated $64.35M of operating cash flow and spent $36.02M on capital expenditures. That left free cash flow of $28.33M, down 22.5% from $36.54M a year earlier, or 8.2% of revenue.

Castle Biosciences Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Castle Biosciences, Inc. (CSTL) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-24.1618.25-57.47-67.14-31.29-10.285.28-6.37-12.37
Depreciation & Amortization40.7716.0012.3310.543.410.470.360.320.31
Deferred Income Tax-6.231.40-0.22-1.88-8.740.00-2.280.27-0.16
Stock Based Compensation45.8950.3251.2236.3221.748.311.250.290.11
Change in Working Capital13.60-14.13-6.63-0.01-4.109.150.04-7.36-0.64
Change in Accounts Receivable6.88-12.64-14.93-6.22-4.631.66-0.90-8.41-0.43
Change in Inventory-2.14-0.19-3.96-1.680.33-0.98-0.36-0.58-0.12
Change in Accounts Payable3.08-4.375.710.58-0.180.170.560.200.37
Change in Other Working Capital5.79-0.856.567.310.388.300.741.43-0.47
Other Operating Activities-5.53-5.57-4.86-19.500.001.382.370.540.52
Net Cash from Operating Activities64.3564.87-5.63-41.66-18.989.877.02-12.29-12.23
Investing Activities
Capital Expenditures-36.02-28.33-13.62-5.63-3.48-4.75-0.94-0.28-0.49
Acquisitions-18.730.020.00-26.97-63.180.000.000.000.00
Purchases of Investments-188.71-205.73-189.08-134.690.000.000.000.000.00
Sales/Maturities of Investments190.73183.90186.500.000.000.000.000.000.00
Other Investing Activities-7.640.000.010.740.010.000.000.000.00
Net Cash from Investing Activities-60.37-50.14-16.18-166.55-66.66-4.75-0.94-0.28-0.49
Financing Activities
Debt Repayment-0.12-0.10-0.14-0.12-0.01-27.3620.925.428.57
Common Stock Issued2.215.000.000.000.00333.2565.9310.420.29
Common Stock Repurchased0.00-8.760.000.000.000.000.000.000.00
Other Financing Activities-9.05-0.10-2.161.645.433.211.4410.380.29
Net Cash from Financing Activities-6.966.14-2.301.525.42305.8988.2915.848.87
Summary
Net Change in Cash-2.9820.87-24.11-206.69-80.22311.0194.373.27-3.86
Cash at Beginning of Period119.7198.84122.95329.63409.8598.854.481.215.07
Cash at End of Period116.73119.7198.84122.95329.63409.8598.854.481.21
Free Cash Flow28.3336.54-19.25-47.29-22.475.116.08-12.57-12.73
Supplemental Disclosures
Interest Paid-0.430.010.020.001.98---
Income Taxes Paid-2.500.200.120.020.10---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Castle Biosciences Cash Flow

What is Castle Biosciences's free cash flow?

Castle Biosciences generated free cash flow of $28.33M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of $64.35M minus $36.02M of capital expenditures. That was down 22.5% from $36.54M a year earlier. Free cash flow equaled 8.2% of revenue.

How much does Castle Biosciences spend on capital expenditures?

Castle Biosciences spent $36.02M on capital expenditures in fiscal 2025, compared with $28.33M a year earlier. That equals 56.0% of operating cash flow.

Does Castle Biosciences pay dividends or buy back shares?

Castle Biosciences's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition